Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease

P. Tall*, M. A. Qamar*, L. Batzu, V. Leta, C. Falup-Pecurariu, K. Ray Chaudhuri

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)

Abstract

Continuous drug delivery (CDD) has emerged as a feasible and pragmatic therapeutic option for dopamine replacement therapy in advanced Parkinson’s disease (PD). CDD aims to mimic the physiological tonic dopamine release from striatal dopaminergic neurons and thus reduces the severity and duration of motor and non-motor fluctuations partly related to pulsatile levodopa stimulation. Non-motor symptoms and fluctuations are ubiquitous in PD and include sleep dysfunction, a problem that occurs in over 90% of PD patients across all stages, from prodromal to palliative. In this review, we discuss the currently available and in development non-oral dopaminergic CDD strategies with a focus on their efficacy in the treatment of the burdensome sleep dysfunction in PD.

Original languageEnglish
Pages (from-to)1443-1449
Number of pages7
JournalJournal of Neural Transmission
Volume130
Issue number11
DOIs
Publication statusPublished - Nov 2023

Keywords

  • Apomorphine
  • Continous drug delivery
  • LCIG
  • LECIGON
  • Levodopa
  • Park-sleep
  • Parkinsons
  • Sleep

Fingerprint

Dive into the research topics of 'Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease'. Together they form a unique fingerprint.

Cite this